ADMA (ADMA Biologics) Ending Cash Position: $138.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.72
GF Value $18.11
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Ending Cash Position?

ADMA Biologics ADMA -1.19% 64 Ending Cash Position is $138.2 Mil as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.11 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ADMA Biologics's Ending Cash Position for the quarter that ended in Mar. 2026 was $138.2 Mil.

ADMA Biologics's quarterly Ending Cash Position increased from Sep. 2025 ($61.4 Mil) to Dec. 2025 ($87.6 Mil) and increased from Dec. 2025 ($87.6 Mil) to Mar. 2026 ($138.2 Mil).

ADMA Biologics's annual Ending Cash Position increased from Dec. 2023 ($51.4 Mil) to Dec. 2024 ($103.1 Mil) but then declined from Dec. 2024 ($103.1 Mil) to Dec. 2025 ($87.6 Mil).

ADMA Biologics Ending Cash Position Related Terms

ADMA Biologics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Ending Cash Position Chart

ADMA Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.09 86.52 51.35 103.15 87.63

ADMA Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.63 90.29 61.39 87.63 138.15
ADMA
64GF Score
ADMA Biologics Inc ADMA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ADMA Biologics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=103.147+-15.517
=87.6

ADMA Biologics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=87.63+50.523
=138.2

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $138.2 Mil mean?
ADMA Biologics (ADMA) has a Ending Cash Position of $138.2 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' Ending Cash Position too high?
ADMA Biologics' current Ending Cash Position is $138.2 Mil. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Ending Cash Position compare to ZLAB and HRMY?
ADMA Biologics' Ending Cash Position of $138.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Ending Cash Position is $138.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.11, compared to a current price of $8.72 — trading 51.9% below its estimated fair value. The current Ending Cash Position is $138.2 Mil. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Ending Cash Position is $138.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.72 is trading 51.9% below its estimated GF Value™ of $18.11. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Ending Cash Position: $138.2 Mil
  • GF Value™: $18.11 vs. price of $8.72 (51.9% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.72
Price
$18.11
GF Value